These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33823560)

  • 21. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin.
    Spinal Cord Injury Thromboprophylaxis Investigators
    J Trauma; 2003 Jun; 54(6):1116-24; discussion 1125-6. PubMed ID: 12813332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.
    Cosmi B; Giannella M; Fornaro G; Cristini F; Patacca A; Castagna A; Mazzaferri F; Testa S; Pan A; Lupi M; Brambilla P; Montineri A; Frattima S; Bignami EG; Salvetti M; De Stefano G; Grandone E; Di Perri G; Rozzini R; Stella A; Romagnoli A; Drago F; Viale P
    BMC Infect Dis; 2023 Oct; 23(1):718. PubMed ID: 37875792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
    Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
    J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism.
    O'Brien SH; Kulkarni R; Wallace A; Hamblin F; Burr S; Goldenberg NA
    J Thromb Haemost; 2014 Nov; 12(11):1822-5. PubMed ID: 25182454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
    Bikdeli B; Talasaz AH; Rashidi F; Bakhshandeh H; Rafiee F; Rezaeifar P; Baghizadeh E; Matin S; Jamalkhani S; Tahamtan O; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Khalili H; Yadollahzadeh M; Riahi T; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Amin A; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Dobesh PP; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
    Thromb Haemost; 2022 Jan; 122(1):131-141. PubMed ID: 33865239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
    Weitz JI; Cao C; Eriksson BI; Fisher W; Kupfer S; Raskob G; Spaeder J; Turpie AG
    Thromb Haemost; 2010 Dec; 104(6):1150-7. PubMed ID: 20886185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial.
    Pai M; Adhikari NKJ; Ostermann M; Heels-Ansdell D; Douketis JD; Skrobik Y; Qushmaq I; Meade M; Guyatt G; Geerts W; Walsh MW; Crowther MA; Friedrich JO; Burry L; Bellomo R; Brandão da Silva N; Costa Filho R; Cox MJ; Alves Silva S; Cook DJ;
    PLoS One; 2018; 13(6):e0198285. PubMed ID: 29856817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
    Albertsen IE; Larsen TB; Rasmussen LH; Overvad TF; Lip GY
    Drugs; 2012 Sep; 72(13):1755-64. PubMed ID: 22876779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients.
    DeBiase C; Giuliano CA; Doshi M; Ganoff M; Alexander Paxton R
    Pharmacotherapy; 2021 May; 41(5):424-429. PubMed ID: 33641194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
    Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
    BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.
    Bain E; Wilson A; Tooher R; Gates S; Davis LJ; Middleton P
    Cochrane Database Syst Rev; 2014 Feb; (2):CD001689. PubMed ID: 24519568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin.
    Spinal Cord Injury Thromboprophylaxis Investigators
    J Trauma; 2003 Jun; 54(6):1111-5. PubMed ID: 12813331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients.
    Li G; Cook DJ; Levine MAH; Guyatt G; Crowther M; Heels-Ansdell D; Holbrook A; Lamontagne F; Walter SD; Ferguson ND; Finfer S; Arabi YM; Bellomo R; Cooper DJ; Thabane L;
    Medicine (Baltimore); 2015 Sep; 94(36):e1479. PubMed ID: 26356708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
    Samuel S; To C; Ling Y; Zhang K; Jiang X; Bernstam EV
    J Thromb Thrombolysis; 2023 Apr; 55(3):439-448. PubMed ID: 36624202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
    Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.